Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody

NCT02189837 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Hyperlipidemia and Mixed Dyslipidemia

Interventions

BIOLOGICAL: Evolocumab
DRUG: Atorvastatin
DRUG: Placebo to Evolocumab
DRUG: Placebo to Atorvastatin

Sponsor

Amgen